Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Get Free Report) have earned an average recommendation of “Moderate Buy” from the nine ratings firms that are currently covering the company, Marketbeat Ratings reports. Six investment analysts have rated the stock with a hold recommendation, one has issued a buy recommendation and two have issued a strong buy recommendation on the company. The average 1 year price target among brokers that have covered the stock in the last year is $32.00.
Several research firms recently issued reports on CPRX. Wall Street Zen lowered Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, May 9th. Citigroup downgraded shares of Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $35.00 to $31.50 in a report on Friday, May 8th. Truist Financial upgraded shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, March 25th. Zacks Research downgraded shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Monday, May 18th. Finally, Stephens set a $32.00 price target on shares of Catalyst Pharmaceuticals in a report on Thursday, May 7th.
View Our Latest Stock Report on CPRX
Catalyst Pharmaceuticals Stock Down 0.1%
Institutional Trading of Catalyst Pharmaceuticals
Institutional investors and hedge funds have recently made changes to their positions in the stock. Parkside Financial Bank & Trust increased its position in Catalyst Pharmaceuticals by 17.6% in the fourth quarter. Parkside Financial Bank & Trust now owns 3,138 shares of the biopharmaceutical company’s stock worth $73,000 after buying an additional 469 shares during the period. Oregon Public Employees Retirement Fund grew its position in shares of Catalyst Pharmaceuticals by 1.8% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 26,428 shares of the biopharmaceutical company’s stock worth $617,000 after acquiring an additional 472 shares during the last quarter. PNC Financial Services Group Inc. increased its holdings in shares of Catalyst Pharmaceuticals by 4.7% in the 1st quarter. PNC Financial Services Group Inc. now owns 10,554 shares of the biopharmaceutical company’s stock worth $261,000 after acquiring an additional 474 shares during the period. Jones Financial Companies Lllp increased its holdings in shares of Catalyst Pharmaceuticals by 14.0% in the 3rd quarter. Jones Financial Companies Lllp now owns 4,061 shares of the biopharmaceutical company’s stock worth $79,000 after acquiring an additional 498 shares during the period. Finally, Lifestyle Asset Management Inc. increased its holdings in shares of Catalyst Pharmaceuticals by 3.4% in the 4th quarter. Lifestyle Asset Management Inc. now owns 16,835 shares of the biopharmaceutical company’s stock worth $393,000 after acquiring an additional 553 shares during the period. 79.22% of the stock is currently owned by institutional investors and hedge funds.
Catalyst Pharmaceuticals Company Profile
Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.
The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).
Featured Stories
- Five stocks we like better than Catalyst Pharmaceuticals
- Flying Under the Radar: Lockheed Martin’s $2.8B Stealth Setup
- Bread’s Comeback Is Real—But Is the Easy Money Gone?
- Ollie’s Stock Has Lagged Despite Earnings Beats—What’s Holding It Back?
- Fox Captures The Living Room With $22B Roku Buy
Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
